Why is it difficult for vaccine companies to transfer core technology?

<Anchor> After

evaluating the diplomatic relations of this vaccine with medical reporter Jo Dong-chan, I will answer any remaining questions.

of'Vaccine

[Medical Reporter Dong-Chan Jo: We are able to make mRNA vaccines in our land, but we have secured a more favorable position in the vaccine purchase negotiations. However, in order to become a vaccine sustenance country, you have to secure the core technology, which is a pity. Although we have achieved achievements in the pharmaceutical industry, we believe that there are also challenges left.]

[Cho Dong-chan, medical reporter: It's because the core technology patents are intricately entangled. Let’s look at the mRNA patents released by Nature. The core technology that Modena is using is patented with 13 institutions including the National Institutes of Health and the University of Pennsylvania, as well as two German companies, rivals Pfizer and Tesla. Because of this, vaccine makers say that it is better to donate finished products than to transfer technology.]

[Cho Dong-chan, medical reporter: Samsung Biologics will receive raw materials for mRNA vaccines from Modena and make them in large quantities using a state-of-the-art biological method using E. coli. However, in order to stably transport and store the mRNA raw material at this time, a special packaging technology called LNP is required, and Modena said that this would be done. Conversely, the fact that domestic production can be commissioned by August means that the core technology has not been transferred. Through this vaccine partnership, we can look forward to the transfer of key technologies in the future.]

[Medical Reporter Dongchan Jo: The common thing between the 13 organizations involved in the mRNA core technology patents shown above is that they have been soaked in their feet from the very beginning of vaccine development. It's not easy to put a spoon on the finished table. This is a technology map for mRNA vaccines released by Nature. To make mRNA raw materials, dozens of cutting-edge technologies are required, including nanoscience, geology, cytology, and immunology. In order for the Korea-US vaccine cooperation to bear true fruit, it can be said that in the long run, domestic universities and companies will settle on the map you saw earlier.